Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Jonas Grumby who wrote (645)	4/29/1998 6:08:00 AM
From: Bwe	Read Replies (1) \| Respond to of 1686

>>>Stanley..it is not JUST the lawsuit. Biogen in under-performing the Nasdaq AND ITS OWN SECTOR. Look at the chart..it is flaccid. Also notice the double top.<<< These assertions are not quite true, Mr. Grumby: - BGEN is up 21% YTD vs 17% for the NASDAQ Comp - The IBD Med/Healthcare sector index is up 12%. The High Tech index is up 14%. - The stock gave a RS buy signal in March at $48. These RS signals to a point & figure chartist indicate a period of outperformance to come for quite a while. The price of a stock is divided by the DOW each week and to give a buy signal indicates the stock is doing better than the DOW and should continue to do so. - The stock needs to get to $50 to give a "triple top" p&f buy signal. Currently the stock is on a p&f sell from $45. Statistics, as beauty, is often in the eye of the beholder. Regards, Bruce